// App-Quantinova.ai

879 : Marked Suppression of Posttransplant Alloantibody Production and Primed B cell Function In Vivo by mTOR Inhibition Compared to Calcineurin Inhibition

Researchers

Presenter

  • C. Wright

Principal Investigators

  • J. Zimmerer

  • T. Pham

  • G. Bumgardner

Medical Centers

  • Department of Pathology, The Ohio State University, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 40

  • Interleukin 4

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Tacrolimus

  • Rapacan

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved